Organisation › Details

Orchard Therapeutics (Group)

Orchard Therapeutics is a fully integrated commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies. Orchard’s portfolio of autologous ex vivo gene therapies includes Strimvelis®, the first autologous ex vivo gene therapy approved by the European Medicines Agency for adenosine deaminase severe combined immunodeficiency (ADA-SCID). Additional programs for neurometabolic disorders, primary immune deficiencies and hemoglobinopathies include three advanced registrational studies for metachromatic leukodystrophy (MLD), ADA-SCID and Wiskott-Aldrich syndrome (WAS), clinical programs for X-linked chronic granulomatous disease (X-CGD) and transfusion-dependent beta-thalassemia (TDBT), as well as an extensive preclinical pipeline. Orchard currently has offices in the U.K. and the U.S., including London, San Francisco and Boston. *

 

Period Start 2015-09-02 established
Products Industry gene therapy
  Industry 2 DRUGS, ORPHAN
Persons Person Rothera, Mark (Orchard Therapeutics 201708– CEO before PTC Therapeutics + Aegerion + Shire Human Genetic Therapies)
  Person 2 Thomas, Frank (Orchard Therapeutics 201801– CFO + CBO before AMAG Pharmaceuticals + Molecular Biometrics Inc)
     
Region Region London, Greater London
  Country United Kingdom (GB)
  Street 108 Cannon Street
  City EC4N 6EU London
  Tel +44-203-384-6700
    Address record changed: 2019-01-08
     
Basic data Employees n. a.
  Currency USD
  Annual sales 2,076,000 (sales, product, consolidated (2018) 2018-12-31)
  Profit -230,495,000 (2018-12-31)
  Cash 335,844,000 (2018-12-31)
     
    * Document for �About Section�: Orchard Therapeutics Ltd.. (1/7/19). "Press Release: Orchard Therapeutics Highlights Recent Accomplishments and 2019 Strategic Priorities as a Global Leader in Gene Therapy". Boston & London.
     
   
Record changed: 2019-07-13

Advertisement

Picture [LSUK] Life-Sciences-UK.com – The Business Web Portal 650x99px

More documents for Orchard Therapeutics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

[iito] Business Intelligence – The Elephants Are Coming 560x113px




» top